Table 2.
Correlations between changes in oxidative stress-related biomarkers, duration of diabetes, eGRF and the age of the patients.
| Duration | eGRF | Age | AOPP | AGEs | TBARS | FRAP | ROS | Carbonyl Residues | |
|---|---|---|---|---|---|---|---|---|---|
| Duration | |||||||||
| eGRF | −0.6934 **** | ||||||||
| Age | 0.4243 * | −0.5970 *** | |||||||
| AOPP | −0.2149 | 0.0421 | 0.2980 | ||||||
| AGEs | 0.6587 **** | −0.6825 **** | 0.5500 ** | −0.1214 | |||||
| TBARS | −0.3783 * | 0.0814 | 0.1575 | 0.6358 *** | −0.2406 | ||||
| FRAP | −0.0172 | 0.2041 | 0.0182 | 0.0411 | 0.0405 | 0.0592 | |||
| ROS | −0.1504 | 0.1554 | −0.0942 | −0.2483 | −0.1995 | −0.0253 | −0.1191 | ||
| Carbonyl Residues | −0.2661 | 0.1154 | 0.2785 | 0.6948 **** | 0.0514 | 0.5342 ** | 0.3504 * | −0.2148 | |
| Fpg Sites | 0.5659 *** | −0.4055 * | 0.3473 | −0.1654 | 0.3887 * | −0.2485 | 0.2160 | 0.0257 | 0.0206 |
**** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. eGRF: estimated glomerular filtration rate; AOPP: Advanced oxidation protein products; AGEs: advanced glycation end products; TBARS: thiobarbituric acid reactive substances; FRAP: ferric reducing ability of plasma; Fpg sites: formamidopyrimidine DNA glycosylase sites.